Skip to main content
. 2021 Nov 30;13(12):2400. doi: 10.3390/v13122400

Figure 1.

Figure 1

Frequencies of peripheral blood immune cells after Selgantolimod (SLGN) oral administration in healthy subjects. Flow cytometric analysis of PBMCs from BL (Pre) and 8 h (post-treatment) from individuals administered placebo (n = 5) or indicated dosage of SLGN (1.5 mg (n = 9) and 3.0 mg (n = 12)). Representative figures show gating for (A) MAIT (CD161+Vα7.2+), (B) CD14+HLA-DR+ monocytes and (C) CD123+ pDCs and CD11c+ mDCs. Comparative analyses of frequencies of immune cell subsets from baseline (BL) and 8 h samples in placebo or SLGN treated individuals (1.5 or 3.0 mg) for (D) MAIT, (E) monocytes, (F) mDCs and (G) pDCs are shown. Significance calculated by a Wilcoxon matched-pairs signed-rank test. p values ≤ 0.05 *, 0.01 ** and 0.0001 **** show grades of significance. ns: no significance.